ARVNArvinas Inc.Finished
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Breast Cancer
1Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.4
5 insiders sold shares within a month
Since May 21, 2026 · was worth 10, fading over time
Worry score1
Score over time
- Stage
- Phase 2
- Patients
- 152 (final count)
- Started
- Feb 15, 2023
- Main results expected
- Jul 13, 2024
- Fully finished
- Jul 25, 2024
- Results posted
- Aug 29, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies
Measured over: Baseline (during screening, prior to Day 1) and Day 15
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.4, since 2026-05-21, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05549505 · record last updated 2025-08-29 · checked 2026-11-09 15:47 UTC